BridgeBio Oncology
BBOT
42 hedge funds and large institutions have $658M invested in BridgeBio Oncology in 2025 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 16 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
270% more capital invested
Capital invested by funds: $178M → $658M (+$480M)
50% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 16
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
24% more funds holding
Funds holding: 34 → 42 (+8)
16.67% less ownership
Funds ownership: 88.41% → 71.74% (-17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$156M |
| 2 |
DM
Deerfield Management
New York
|
+$50.9M |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$34.3M |
| 4 |
AI
Alphabet Inc
Mountain View,
California
|
+$29.4M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$29.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sculptor Capital
New York
|
-$8.5M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$6.39M |
| 3 |
HCI
Harraden Circle Investments
New York
|
-$6.05M |
| 4 |
Millennium Management
New York
|
-$5.5M |
| 5 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
-$4.73M |
BBOT Hedge Fund Activity: Q3 2025 in Review
42 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q3 2025, worth a combined $658M — up 270% from $178M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new BBOT positions and 16 closed out — a net gain of 8 holders — while 10 added to existing stakes and 7 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $156M. The largest seller was Sculptor Capital, exiting entirely with an estimated $8.5M sold.
- 42 institutional investors held BridgeBio Oncology (BBOT) as of Q3 2025, up from 34 in Q2 2025.
- Funds reported $658M of BridgeBio Oncology stock for Q3 2025, up 270% quarter-over-quarter.
- 24 funds opened new BridgeBio Oncology positions in Q3 2025 and 16 closed out, a net change of +8 holders.
- The largest BridgeBio Oncology buyer in Q3 2025 was Cormorant Asset Management, an estimated $156M added.
- The largest BridgeBio Oncology seller in Q3 2025 was Sculptor Capital, an estimated $8.5M sold.
Based on aggregated 13F filings for Q3 2025.